COVID-19, SARS-CoV-2, conjugate vaccine, heterologous immunization scheme, subunit vaccine
conjugate-vaccine, SARS-COV-2, COVID-19 Vaccine, heterologous scheme, RBD-subunit vaccine, vaccine efficacy
conjugate vaccine, heterologous schedule, COVID-19, recombinant RBD, phase IIb clinical trial